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ORIGINAL ARTICLE
Expression of p89c-Mybex9b, an alternatively spliced form
of c-Myb, is required for proliferation and survival of
p210BCR/ABL-expressing cells
G Manzotti1, SA Mariani2, F Corradini1, R Bussolari1, V Cesi3, J Vergalli2, G Ferrari-Amorotti1, V Fragliasso1, AR Soliera1,
S Cattelani1, G Raschella`3, TL Holyoake4 and B Calabretta1,2
The c-Myb gene encodes the p75c-Myb isoform and less-abundant proteins generated by alternatively spliced transcripts. Among
these, the best known is p89c-Mybex9b, which contains 121 additional amino acids between exon 9 and 10, in a domain involved
in protein–protein interactions and negative regulation. In hematopoietic cells, expression of p89c-Mybex9b accounts for 10–15% of
total c-Myb; these levels may be biologically relevant because modest changes in c-Myb expression affects proliferation and
survival of leukemic cells and lineage choice and frequency of normal hematopoietic progenitors. In this study, we assessed
biochemical activities of p89c-Mybex9b and the consequences of perturbing its expression in K562 and primary chronic myeloid
leukemia (CML) progenitor cells. Compared with p75c-Myb, p89c-Mybex9b is more stable and more effective in transactivating
Myb-regulated promoters. Ectopic expression of p89c-Mybex9b enhanced proliferation and colony formation and reduced imatinib
(IM) sensitivity of K562 cells; conversely, specific downregulation of p89c-Mybex9b reduced proliferation and colony formation,
enhanced IM sensitivity of K562 cells and markedly suppressed colony formation of CML CD34þ cells, without affecting the levels
of p75c-Myb. Together, these studies indicate that expression of the low-abundance p89c-Mybex9b isoform has an important role
for the overall biological effects of c-Myb in BCR/ABL-transformed cells.
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INTRODUCTION
The proto-oncogene c-myb encodes a transcription factor that is
expressed predominantly in immature hematopoietic, epithelial
and endothelial cells and in many tumor types1,2 and is
downregulated as cells become more differentiated.3
In hematopoietic progenitor cells, c-Myb has an important role in
the control of cell proliferation, survival and differentiation;4 in vitro,
downregulation of c-Myb expression leads to decreased proliferation
and colony formation of myeloid progenitors,5 whereas loss of c-Myb,
in vivo, is embryonically lethal due to failure of fetal hematopoiesis.6
Conditional knockout of c-Myb expression in adult hematopoietic
stem cells causes loss of self-renewal due to impaired proliferation
and accelerated differentiation,7 suggesting that c-Myb has an
essential role also in bone marrow primitive hematopoiesis.
Constitutive overexpression of c-Myb in myeloid and erythroid cell
lines blocks differentiation and prevents maturation-associated
growth arrest.8,9 Aberrant c-Myb expression has been detected in
several malignancies including T-cell leukemia,10 chronic myeloid
leukemia (CML), acute myeloid leukemia,11,12 colorectal cancer,13
breast cancer14 and, more recently, adenoid cystic carcinomas.15 In
CML, the increased expression of c-Myb is, in part, due to enhanced
protein stability via BCR/ABL-regulated activation of PI-3K/Akt/GSKIIIb-
dependent pathways;16,17 this altered regulatory mechanism may
explain the requirement of c-Myb for in vitro proliferation and survival
of leukemic progenitor cells18,19 and for leukemogenesis in mice.20
Leukemic blast cells appear to rely on c-Myb expression more
than their normal counterpart,21 suggesting that this differential
requirement for c-Myb may be exploited therapeutically.
The requirement of c-Myb may depend on its ability to
modulate the expression of genes (that is, CD34, c-kit, c-myc,
flt-3 and Bcl-2) with important roles for the proliferation and
survival of hematopoietic cells.22–26 c-Myb also regulates the
expression of cyclin B1, contributing to the control of the G2/M
phase of the cell cycle, in addition to its role during G1/S-phase
transition.27
More recently, we found that c-Myb activates, in a DNA-binding
manner, the expression of Slug and it promotes, via Slug,
the homing of K562 cells to the bone marrow.28
The main product of the c-myb gene is a 75KDa nuclear protein
that contains three functional domains: (i) an N-terminal
DNA-binding domain that specifically binds to the sequence
PyAACG/TG; (ii) a centrally-located transcription activation
domain; and (iii) a C-terminal negative regulatory domain (NRD),
which includes a leucine zipper and an EVES motif that modulate
the activity of c-Myb via inter-and intra-molecular interactions.29,30
Alternatively, spliced c-myb transcripts have been detected in
hematopoietic cells of several species, including humans.31–33 The
best-characterized of these transcripts includes a 363 bp segment
between exons 9 and 10 (designated as exon 9b in humans),
which is translated into 121 additional amino acids that disrupt
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the NRD domain.34,35 p89c-Mybex9b represents 10–15% of total
c-Myb protein in hematopoietic cells and has, apparently,
the same properties of the predominant p75c-Myb species: it
localizes into the nucleus and binds to the same DNA-binding
sequence.36,37 However, the 121 amino acids added by exon 9b
could, in principle, enhance and/or modify the activity of
the p89c-Mybex9b isoform by disruption of the intra- and/or
inter-molecular interactions that may regulate stability and
transactivation activity of c-Myb.38
The function and requirement of the p89c-Mybex9b isoform is
understood only in part: it appears to transactivate the expression
of certain c-Myb targets more effectively than the predominant
p75c-Myb isoform,39 and yet the specific knockout of p89c-Mybex9b
expression has no deleterious consequences on mammalian
hematopoiesis and development,40 suggesting that its loss is
compensated by expression of p75c-Myb.
However, it is unknown whether expression of p89c-Mybex9b is
required for the proliferation and survival of transformed
hematopoietic cells independently of p75c-Myb expression.
We show here that p89c-Mybex9b is more stable and has higher
transactivation activity than p75c-Myb; moreover, its specific
downregulation impairs proliferation and colony formation and
enhances the imatinib (IM) sensitivity of BCR/ABL-expressing cells,
in spite of unperturbed expression of p75c-Myb.
MATERIALS AND METHODS
Plasmids
Mig-RI-c-Myb-HA and Mig-RI-D(358–452)c-Myb were obtained as
described.17
Cyclin B1-Luc-pGL3 was a gift from the late Dr AM Gewirtz (University
of Pennsylvania, Philadelphia, PA, USA). SLUG-Luc-pGL3 was recently
described.28
MSCV-p89c-Mybex9b: p89c-Mybex9b was amplified from human Ph1 K562 cells
by reverse-transcription PCR using exon 9b-specific primers (Fw 50-GCCCT
CGAGATGGACTACAAGGATGACGATGACAAG-30 and Rv 50-ACTGCTGACGTC
AGCAAATATGA-30 ; Fw 50-TCATATTTGCTGACGTCAGCAGT-30 and Rv 50-CGG
GAATTCTCACATGACCAGCGTCCGGG-30) designed to generate 50 and 30
fragments. They were digested with XhoI/AatII and AatII/EcoRI, respectively,
and then ligated to XhoI/EcoRI-digested MSCV.
MSCV-p89c-Mybex9bMUT was generated by mutating four nucleotides of
MSCV-p89c-Mybex9b by two subsequent site-directed mutagenesis accord-
ing to manufacturer’s instructions (QuickChange II site-directed mutagen-
esis kit, Stratagene, Santa Clara, CA). Mutated primers were: 50-CCACTGGTC
ATCCTCCGGAAAAAACGGGGCCA-30 and its reverse complement (first
mutagenesis); and 50-CACAGCACAATTCCATTAGTCATCCTCCGGAAA-30 and
its reverse complement (second mutagenesis).
Mig-RI-p89c-Mybex9 plasmid was generated by digesting MSCV-p89c-Mybex9b
with XhoI/AatII and AatII/EcoRI and ligating the two fragments into
XhoI/EcoRI-digested Mig-RI.
MSCV-p89c-Mybex9b_shMUT and MSCV-p75c-Myb_shMUT, the mutant forms
of p89c-Mybex9b and p75c-Myb, not inhibitable by the doxycycline (DOX)-
regulated c-Myb-short hairpin RNA (shRNA)_pLVTSH lentivirus (gift of
Dr TJ Gonda, Brisbane University, Australia),41 were generated using the
In-Fusion HD Cloning Kit (Clontech Laboratories, Mountain View, CA, USA).
The c-Myb-coding region was amplified from MSCV-p89c-Mybex9b and
MSCV-p75c-Myb used as templates with primer set A (Fw 50-CGCCGGAATTA
GATCTATGGACTACAAGGATGACGATGAC-30 , Rv 50-AATTCTAACAGATTCTTA
ACATTATCCAG-30 , which amplify a region of 1221 bp common to both
p89c-Mybex9b and p75c-Myb) and primer set B (Fw 50-CGCCGAGACGCTCCA
ATTTATAGATTCT-30 , Rv 50-ATTCGTTAACCTCGAGTCACATGACCAGCGTCC-30 ,
which amplify a region of 1094 and 732 bp of p89c-Mybex9b and p75c-Myb,
respectively). Mutated bases in the primers are underlined, those targeted
by the shRNA are in italics. Mutations maintain same amino acids as in
p89c-Mybex9b and p75c-Myb. Amplification products and linearized MSCV
retroviral vector were ligated and cloned according to the kit’s instructions.
Correct mutations were confirmed by sequencing.
Cells and culture conditions
293T cells and parental and derivative K562 cell lines were maintained as
described.42 Derivative K562 cell lines (D(358–452)c-Myb, p89c-Mybex9b,
c-Myb shRNA or c-Myb shRNA expressing p89c-Mybex9b_shMUT or
p75c-Myb_shMUT) were established by retroviral infection and isolation
of green fluorescent protein-positive cells or selection with puromycin.
Peripheral blood (granulocyte colony-stimulating factor (G-CSF) mobi-
lized) normal CD34þ cells were purchased from Stem Cell Technologies
(Stem Cell Technologies, Vancouver, British Columbia, Canada).
CML chronic-phase fresh leukapheresis or peripheral blood samples were
obtained with informed written consent from five patients. Samples were
enriched for CD34þ and cultured as described.43
Transient transfection and dual-luciferase reporter assay
The Mig-RI D(358–452)c-Myb or p89c-Mybex9 (3mg) was co-transfected with
cyclin B1-Luc-pGL3 or SLUG-Luc-pGL3 (1 mg) and Renilla luciferase (0.02mg)
into 106 K562 cells using nucleofector kit V (Amaxa; Lonza Group, Basel,
Switzerland) according to the manufacturer’s protocol. After 48 h, cells
were diluted 1:5 in fresh medium and cultured for an additional 6–8 h. Cells
were then lysed (100ml of passive lysis buffer; Promega, Madison, WI, USA)
and Firefly and Renilla luciferase activities were measured on a
luminometer using the dual-luciferase reporter assay kit (Promega). For
the assay in 293T cells, cells were seeded into six-well plates at 5 104 cells
per well. The following day, DNA (5 mg of reporter plasmid, 5 mg of effector
plasmid and 0.5mg of Renilla luciferase) was transfected using ProFection
Mammalian Transfection System-Calcium Phosphate (Promega) following
the manufacturer’s protocol. Cells were washed 16 h after transfection and
incubated in fresh medium for an additional 24 h. At 40 h post transfection,
cells were lysed in 500ml of passive lysis buffer per well (Promega) and
Firefly and Renilla luciferase activities were measured as described. All the
measurements were performed in triplicate.
Chromatin immunoprecipitation and co-immunoprecipitation
For chromatin immunoprecipitation experiments performed in Mig-RI-
p89c-Mybex9b-FLAG K562 cells, samples were prepared as described.44
IPs were performed with anti-c-Myb antibody (30mg; clone 1–1, Upstate
Biotechnology, Millipore Corporation, Billerica, MA, USA) or anti-FLAG
antibody (30mg; clone M2, Sigma-Aldrich, St Louis, MO, USA) or anti-rabbit
IgG or without antibody at 4 1C for 1 h with rotation. Immune complexes
were collected with 45 ml of protein G-agarose beads at 4 1C overnight with
rotation. Recovered DNA (2ml) was used as a template for Real-Time PCR
using GoTaq Real-Time PCR Mix (Promega) and primers on the 50-flanking
region of the human cyclin B127 or SLUG28 promoter. Data were analyzed
with the percent input method: percentage of input was calculated by
100 2(CtInputCtEnriched).
For co-immunoprecipitations, 293T cells were transfected with plasmids
expressing tagged c-Myb and lysates were immunoprecipitated with
Anti-FLAG M2-Affinity gel (Sigma-Aldrich) following the manufacturer’s
instructions. Tagged proteins were detected by anti-FLAG M2-peroxidase-
HRP (Sigma-Aldrich) and anti-HA-peroxidase High Affinity 3F10
(Roche, Nutley, NJ, USA).
Measurement of c-Myb half-life
To asses the half-life of p75c-Myb and p89c-Mybex9b, cells (pre-treated or not
with 2 mM IM for 16 h) were treated with cycloheximide (25mg/ml) for 2 h to
suppress protein synthesis. Samples were collected every 30min and
lysates (100 mg each) analyzed by anti-c-Myb western blotting. Later, bands
corresponding to the c-Myb isoforms and to b-actin as loading control
were scanned and densitometric analysis was carried out with ImageJ
Software (National Institutes of Health). The half-lifes of p75c-Myb and
p89c-Mybex9b were calculated using the formula: t1/2¼ (0.693xt)/ln(Nt/No)
as described.17
Small interfering RNA (siRNA) transfection and real-time PCR
Human c-Myb siRNA pool (catalog no. L-003910-00-0005) and control
siRNAs (catalog no. D-001810-10-05) were purchased from Dharmacon,
Thermo Fisher Scientific (Lafayette, CO, USA).
p89c-Mybex9b-siRNA-1 and p89c-Mybex9b-siRNA-2 were customized through
the Dharmacon web site and purchased from Sigma-Aldrich. A total of 106
K562 cells were resuspended in Ingenio Electroporation Solution (Mirus Bio
LLC, Madison, WI, USA) and mixed with 5 mg of each siRNA. The solution
was added to Ingenio Cuvettes (Mirus Bio LLC) and electroporated
according to Amaxa Nucleofector II using program T-16. Then, cells were
diluted in 2ml of Iscove’s modified Dulbecco’s medium supplemented
with 20% fetal bovine serum, penicillin/streptomycin (100 mg/ml each) and
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2mM L-glutamine. 24 h later siRNA electroporation was repeated in order
to downregulate c-Myb expression completely.
Expression of p75c-Myb- and p89c-Mybex9b-specific transcripts was
detected by Real-Time PCR in control or c-Myb pool or p89c-Mybex9b-
siRNA-2-transfected K562 cells using the following primers: p89c-Mybex9b-
specific transcript: Fw 50-AACATCACACAGGCAAAGC-30 and Rv 50-TGAACTC
TCACTCAACATACG-30 ; p75c-Myb-specific transcript: Fw 50-TAGATTCTTTCTT
AAACACTTCC-30 and Rv 50-GTCTCTATGAAATGGTGTTGTAAC-30 ; for normal-
ization, expression of hypoxanthine-guanine phosphoribosyltransferase
was detected with the following primers: Fw 50-AGACTTGCTTTCCTTGGTC
AGG-30 ; Rv 50-GTCTGGCTTATATCCAACACTTCG-30 . Control siRNAs, c-Myb
siRNAs pool and p89c-Mybex9b-siRNA-2 (5mg) were delivered to normal
or CML CD34þ cells using nucleofector kit V, program U-08 (Amaxa;
Lonza Group), according to the manufacturer’s protocol.
Cell proliferation, cell-cycle analysis and colony-formation assay
Proliferation of K562 cells transfected with different siRNAs was assessed
by seeding 1.2 105 cells/ml and counting the cells every 24 h by trypan
blue exclusion.
For induction of apoptosis, parental or derivative K562 cells were seeded
at 2 105 cells/ml and treated with 2 mM IM (1mM added every 12 h)
(LC Laboratories, Woburn, MA, USA). Cells were counted every 24 h by
trypan blue exclusion and percentage of apoptosis evaluated by the
hypotonic propidium iodide method45 through Coulter Epics XL-MCL
(Beckman Coulter Inc., Indianapolis, IN, USA).
G2/M-phase cells were also evaluated by propidium iodide staining.
Phospho-histone-H3 positivity was assessed by Phospho-(Ser10)-histone-H3
(Cell Signalling Technology, Danvers, MA, USA) staining according to the
manufacturer’s instructions.
For colony-formation assays, K562 cells were plated in methylcellulose
(Stem Cell Technologies) with or without IM (1mM; pre-treatment in liquid
culture for 24 h and added to the plates) and with or without doxycycline
(5mg/ml; pre-tratment in liquid culture for 24 h and added to the plates);
colonies were counted 6 days later. CD34þ cells were plated in
methylcellulose supplemented with Cytokine Cocktail CC100 (Stem Cell
Technologies) and colonies were counted 9 days later.
Statistical analyses
Data (presented as the means±s.d. of two or three experiments) were
analyzed for statistical significance by the unpaired, two-tailed Student’s
t-test. P-values of o0.05 were considered statistically significant.
RESULTS
Increased transactivation of c-Myb-regulated promoters by
p89c-Mybex9b
Two c-Myb mutans, D(358–452)c-Myb and D(389–418)c-Myb,
which lack 93 and 30 amino acids, respectively, in the leucine-
zipper-NRD (LZ-NRD) are more potent than wild-type p75c-Myb in
enhancing proliferation and blocking apoptosis of normal and
transformed hematopoietic cells.17
p89c-Mybex9b, a naturally occurring alternatively spliced form of
c-myb, which accounts for approximately 10–15% of total c-Myb
levels, contains an insertion of 121 amino acids in the LZ which
disrupts its structure, presumably preventing the interaction with
regulatory c-Myb-interacting proteins.
A comparison (Figure 1a) of p75c-Myb, p89c-Mybex9b and the
LZ-NRD mutant D(358–452)c-Myb shows that the LZ is altered
in p89c-Mybex9b and in the c-Myb mutant, suggesting that
p89c-Mybex9b may function like the artificial LZ-NRD D(358–452)c-Myb.
The transactivation potential of p89c-Mybex9b, D(358–452)c-Myb,
and p75c-Myb was compared by dual-luciferase assays using
reporter plasmids consisting of a fragment of the Myb-regulated
human cyclin B1 or SLUG promoter driving the luciferase gene
(cyclin B1-Luc or SLUG-Luc).
Following co-transfection of reporter and effector plasmids in
293T cells, expression and transactivation of each c-Myb protein
were analyzed.
Expression of the three c-Myb isoforms was essentially identical
in 293T cells (Figure 1b). p89c-Mybex9b and D(358–452)c-Myb were
slightly more effective than p75c-Myb in transactivation of the
cyclin B1 promoter but not of the SLUG promoter (Figure 1e). The
transactivating ability of the three c-Myb proteins was also tested
in Ph1 K562 cells; because K562 cells express high levels of
endogenous c-Myb, the increase in expression of p75c-Myb in
transfected cells (Figure 1c) was quantitated by densitometry
(Figure 1d), whereas expression of p89c-Mybex9b and D(358–452)
c-Myb was detected because of size differences and quantitated
by densitometry (Figures 1c and d).
Compared with 293T cells, the effects of the c-Myb isoforms in
K562 cells were markedly different: p75c-Myb induced approxi-
mately a three-fold increase in transactivation of the cyclin B1
promoter, whereas p89c-Mybex9b and D(358–452)c-Myb were much
more potent (Bfifteen- and twelve-fold increase, respectively)
(Figure 1f, upper panel); likewise, p89c-Mybex9b and D(358–452)
c-Myb transactivated the SLUG promoter more effectively than
p75c-Myb (Bfive- and six- versus three-fold, respectively) (Figure 1f,
lower panel).
p89c-Mybex9b binds to the human cyclin B1 and SLUG promoters
To assess whether p89c-Mybex9b interacted with the cyclin B1 and
SLUG promoters, we performed chromatin immunoprecipitation
assays in K562 cells overexpressing FLAG-tagged-p89c-Mybex9b
using either an anti-FLAG antibody (which binds only the
ectopically expressed protein) or an anti-c-Myb antibody (which
binds the endogenous and the ectopically expressed protein).
The ability of p89c-Mybex9b to bind the two promoters was assessed
by real-time PCR amplification of a 50-flanking region segment,
which includes putative c-Myb-binding sites (Figures 2a and b,
right). The  122 to þ 177 nucleotide segment of the
cyclin B1 promoter and the  77 to þ 175 segment of the
SLUG promoter were amplified above background in both the
anti-c-Myb and anti-FLAG chromatin IPs, indicating that p89c-
Mybex9b binds to these c-Myb-regulated promoters (Figures 2a
and b, left).
Enhanced stability of p89c-Mybex9b in BCR/ABL-positive cells
In addition to the transactivation ability, we also tested the
stability of p89c-Mybex9b because the insertion of ex9b disrupts the
LZ domain and c-Myb LZ-domain mutant proteins are more stable
than wild-type p75c-Myb.17
Thus, parental and p89c-Mybex9b-expressing K562 cells were
treated with cycloheximide for different times and cell lysates
blotted with an anti-c-Myb antibody to assess half-life of
endogenous p75c-Myb and ectopic p89c-Mybex9b, expressed at
comparable levels. Expression of p75c-Myb was more rapidly down-
modulated of p89c-Mybex9b; by densitometry analysis, the half-life
of p89c-Mybex9b is B90min, nearly 30min longer than that of
p75c-Myb (Figures 3a and b).
Because p210BCR/ABL enhances the stability of c-Myb,17 we also
assessed the half-life of the two c-Myb isoforms in IM-treated cells.
Inhibition of BCR/ABL tyrosine kinase activity decreased the half-
life of p75c-Myb (B35min in IM-treated versus 60min in untreated
cells); in contrast, the half-life of p89c-Mybex9b was unaffected by
treatment with IM (Figure 3c). By densitometry analysis, the half-
life of p89c-Mybex9b in IM-treated cells was B75min longer than
that of p75c-Myb (110 versus 35min, Figure 3d).
Inhibition of p89c-Mybex9b expression suppresses proliferation and
colony formation of K562 cells.
We investigated the role of p89c-Mybex9b expression in trans-
formed cells by assessing whether its specific knockdown has
any effect on the proliferation and clonogenic potential of Ph1
K562 cells.
Two siRNAs targeting two different regions of human exon 9b
c-Myb transcript (siRNA-1 and siRNA-2, Figure 4a) suppressed very
effectively p89c-Mybex9b expression in K562 cells (Figure 4b, left)
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with no effects on levels of the p75c-Myb isoform. As control,
we also used a pool of siRNAs targeting both p75c-Myb and the
p89c-Mybex9b transcripts; transfection with this c-Myb siRNA pool
led to the disappearance of both c-Myb isoforms (Figure 4b, right).
Real-Time PCR using primers specific for p75c-Myb or p89c-Mybex9b
transcripts further demonstrated that silencing of p89c-Mybex9b
DBD
189
189
1891
1
1 358
358
358
452
452 546
402 522 761
640
p75 c-Myb
p89 c-Myb
ex9b
(358-452)
c-Myb
DBD
DBD
TAD
TAD
TAD
NRD
LZ
Ex9b
NRD
NRD
293T
M
SC
V-
p7
5 
c-
M
yb
M
SC
V-
p8
9 
c-
M
yb
Em
pt
y 
ve
ct
or
M
SC
V 
-Δ
(35
8-4
52
)c-
My
b
M
SC
V-
p7
5 
c-
M
yb
M
SC
V-
p8
9 
c-
M
yb
Em
pt
y 
ve
ct
or
0
MigRI
-p75
c-Myb
MigRI
-p89
c-Myb
Effetors
MigRI
-Δ(358-452)
c-Myb
Empty
vector
0.5
1.5
2
2.5
p89 c-Mybp75 c-Myb Δ(358-452) c-Myb
1
N
or
m
al
iz
ed
 d
en
sit
om
et
ric
va
lu
es
M
SC
V 
-Δ
(35
8-4
52
)c-
My
b
p89 c-Myb
p79 c-Myb
Δ(358-452) c-Myb
β-actin
K562
p89 c-Myb
p75 c-Myb
293T K562
1.2 18
*
*
*
16
14
12
10
8
6
4
2
0
*
*
1
0.8
0.6
0.4Fo
ld
 a
ct
iva
tio
n
pG
L3
 - 
cy
cli
n 
B1
 - 
Lu
c
pG
L3
 - 
SL
UG
 - 
Lu
c
Fo
ld
 a
ct
iva
tio
n
Fo
ld
 a
ct
iva
tio
n
Fo
ld
 a
ct
iva
tio
n
0.2
0
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0 0
1
2
3
4
5
6
7
*
*
p75 c-Myb p75 c-Mybp89 c-Myb p89 c-Myb
Effectors Effectors
Δ(358-452)
c-Myb
p75 c-Myb p89 c-Myb
Effectors
Δ(358-452)
c-Myb
p75 c-Myb p89 c-Myb
Effectors
Δ(358-452)
c-Myb
Δ(358-452)
c-Myb
(358-452) c-Myb
β-actin
Figure 1. Transactivation activity of p89c-Mybex9b. (a) Schematic diagram of c-Myb proteins; levels of p75c-Myb, p89c-Mybex9b and D(358–452)
c-Myb in transfected 293T cells (b) and K562 cells (c) used for luciferase assays. Expression of b-actin was detected as loading control; c-Myb
and b-actin were detected by anti-c-Myb (clone 1-1, Upstate Biotechnology) and anti-b-actin antibody (sc-47778, Santa Cruz Biotechnology).
(d) Densitometric analysis of c-Myb protein levels in transfected K562 normalized by corresponding b-actin expression. (e) Luciferase activity
in 293T cells co-transfected with c-Myb plasmids and pGL3-cyclin B1-Luc (upper panel) or pGL3-Slug-Luc (lower panel). Results (from three
and two experiments performed in duplicate, respectively) are expressed as fold activation relative to MSCV empty vector-transfected cells,
after normalization for Renilla luciferase activity. (f, upper panel) Luciferase activity in K562 cells transfected with pGL3-cyclin B1-Luc and
c-Myb plasmids. Results (means of three different experiments) are reported as fold activation relative to the pGL3 empty vector, after
normalization for Renilla activity. (f, lower panel) Luciferase activity in K562 cells transfected with pGL3-Slug-Luc and c-Myb plasmids. Results
(from two independent experiments, performed in duplicate) show fold activation relative to the MSCV empty vector, after normalization
for Renilla activity. Error bars in e and f represent the s.d. of the means. P-values were calculated using unpaired, two-tailed Student’s
t-test, *denotes statistical significance of differences in transactivation activity of p75c-Myb versus p89c-Mybex9b or D(358–452)c-Myb and of
p89c-Mybex9b versus D(358–452)c-Myb.
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expression had no effect on levels of p75c-Myb transcripts
(Supplementary Figure 1).
K562 cells transfected with the c-Myb siRNA pool or with
p89c-Mybex9b-specific siRNAs proliferated less than control
siRNA-transfected cells (Figure 4c); at 48 h, the c-Myb siRNA pool
was more effective than the p89c-Mybex9b-specific siRNAs (54%
versus 30% inhibition, respectively), but at 72 h, the effects were
comparable.
We also assessed the effect of p89c-Mybex9b-specific down-
regulation on colony formation of K562 cells. Thus, cells were
transfected with control or specific siRNAs and 24 h after the
second transfection were plated in methylcellulose (500 cells per
plate) and colonies were counted 6 days later. Cells treated with
control siRNA formed 350±36 colonies (Figure 4d), whereas K562
cells transfected with the c-Myb siRNA pool formed 178±27
colonies; a significant decrease in colony formation was also noted
by plating cells transfected with p89c-Mybex9b-siRNA-2 (230±14
colonies) or p89c-Mybex9b-siRNA-1 (230±11) (Figure 4d).
To assess the specificity of the biological effects induced
by p89c-Mybex9b-siRNA-2, we generated K562-derivative lines
Figure 2. p89c-Mybex9b binds the cyclin B1 and SLUG promoter. Chromatin immunoprecipitation assays show binding (detected by real-time
PCR) of p75c-Myb and p89c-Mybex9 to a segment of the cyclin B1 promoter (a, left) and SLUG promoter (b, left). Error bars denote s.d. of the
means of two experiments performed in triplicate. (a and b, right): partial sequence of the human promoter of cyclin B1 (GenBank: U22364.1)
and SLUG (GenBank: AB300659.1). Putative c-Myb-binding sites located in the 50-untranslated region (italics) are underlined; primers used for
real-time PCR are in bold.
Figure 3. Half-life of p89c-Mybex9b in K562 cells. Representative western blot shows levels of p75c-Myb and p89c-Mybex9b in: (a) cells treated with
cycloheximide only and (c) cells pre-treated for 16 h with 2mM IM before cycloheximide treatment. Levels of b-actin were measured as loading
control. (b–d) Densitometric analysis from two combined experiments assessing the half-life of c-Myb isoforms.
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Figure 4. Effects of p89c-Mybex9b downregulation in K562 cells. (a) Schematic diagram representing the siRNAs target sequences of p89c-Mybex9b
and the mutations in p89c-Mybex9b MUT. (b) Western blot shows levels of p75c-Myb and p89c-Mybex9b in K652 cells transfected with the c-Myb
siRNA pool, c-Myb ex9b-specific siRNAs (sequence 1 and 2) or their relative controls. b-actin levels were measured as control of equal loading.
(c) Cell counts and (d) colony formation of K562 cells transfected with c-Myb siRNA pool or its control (upper) or c-Myb ex9b siRNA 1 or siRNA2
or their scramble control (lower). (e) Levels of p89c-Mybex9b in MSCV-p89c-Mybex9b and MSCV-p89c-Mybex9bMUT K562 cells transfected
with a control or the p89c-Mybex9b-siRNA 2. Expression of b-actin detected as loading control. (f ) Methylcellulose colony formation of
MSCV-p89c-Mybex9b and MSCV-p89c-Mybex9bMUT K562 cells transfected with a control or the p89c-Mybex9b-siRNA 2 (values of cell counts and
number of colonies are given as mean±s.d. of three independent experiments performed in triplicate; * denotes statistical significance of the
differences between scrambled- and siRNA-transfected cells). (g) Levels of p75c-Myb and p89c-Mybex9b in untreated and DOX-treated (24 h) K562
cells expressing a DOX-inducible c-Myb shRNA and transduced with p75c-Myb_shMUT or p89c-Mybex9b_shMUT. Expression of b-actin is detected
as loading control. (h) Colony formation of untreated and DOX-treated cells; values are expressed as % of colonies formed by treated cells,
compared with untreated cells taken as 100% (data are given as mean±s.d. of two independent experiments performed in triplicate;
*denotes statistical significance of the differences between K562 cells with shMUT c-Mybs and cells with only c-Myb shRNA).
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ectopically expressing wild-type p89c-Mybex9b and a mutant,
p89c-Mybex9bMUT, with four nucleotide substitutions in the
sequence targeted by p89c-Mybex9b-siRNA-2; these mutations were
designed to prevent interaction with siRNA-2 while preserving the
amino-acid sequence of the protein (Figure 4a).
MSCV-p89c-Mybex9b and MSCV-p89c-Mybex9bMUT K562 cells were
then transfected with a control or the p89c-Mybex9b-siRNA-2 and
levels of p89c-Mybex9b were tested by western blotting. Levels
of p89c-Mybex9b were undetectable in MSCV-p89c-Mybex9b K562
cells transfected with p89c-Mybex9b siRNA-2 (Figure 4e); in contrast,
expression of p89c-Mybex9b was detected in siRNA-2-transfected
MSCV-p89c-Mybex9bMUT K562 cells, reflecting downregulation of the
endogenous protein but not of the p89c-Mybex9b protein derived
from p89c-Mybex9bMUT, which is not targeted by p89c-Mybex9b-siRNA-2.
As expected, MSCV-p89c-Mybex9b K562 cells transfected with
p89c-Mybex9b-siRNA-2 formed fewer colonies (B50% inhibition) than
the scramble siRNA-transfected counterpart (Figure 4f);
in contrast, there were no significant differences in colony
formation of scrambled- or p89c-Mybex9b-siRNA-2-transfected
MSCV-p89c-Mybex9bMUT K562 cells (Figure 4f), further confirming that
the inhibition of K562 colony formation by p89c-Mybex9b-siRNA-2 is
due to specific downregulation of p89c-Mybex9b expression.
The importance of p89c-Mybex9b expression for K562 colony
formation was also assessed in K562 cells expressing
a DOX-inducible c-Myb shRNA, which downregulates the
p75c-Myb and p89c-Mybex9b isoforms, and carrying the p75c-Myb
or p89c-Mybex9b expression vector non-targetable by the DOX-
inducible c-Myb shRNA (p75c-Myb_shMUT and p89c-Mybex9b_
shMUT, respectively) (Figure 4g). As expected, colony formation
of DOX-treated K562-c-Myb shRNA cells was markedly suppressed
(B80% inhibition); in contrast, expression of p89c-Mybex9b_shMUT
or p75c-Myb_shMUT rescued, in part, the inhibitory effect of the
DOX-inducible c-Myb shRNA (Figure 4h), consistent with redun-
dant and yet non-overlapping effects of the p75c-Myb and the
p89c-Mybex9b-Myb isoforms.
Levels of cyclin B1 are downregulated in p89c-Mybex9b-silenced
K562 cells
The reduced colony formation of c-Myb-silenced (p75c-Myb and/or
p89c-Mybex9b) K562 cells may be caused by changes in the
expression of c-Myb-regulated genes with a role in cell prolifera-
tion. Cyclin B1, a gene with an essential role in the G2/M transition,
is one of the c-Myb targets27 whose change in expression may
explain, in part, the effects of p89c-Mybex9b downregulation.
Indeed, compared with control siRNA-transfected cells, cyclin B1
expression was reduced in K562 cells transfected with the c-Myb
siRNA pool (B45% decrease of cyclin B1 levels); although
expression of p75c-Myb was unaffected, the specific downregula-
tion of p89c-Mybex9 led to a similar decrease (B42%) of cyclin B1
expression (Figures 5a and b).
Figure 5. Effects of p89c-Mybex9b downregulation on cyclin B1 levels and G2/M-phase cells. (a) Western blot shows levels of c-Myb isoforms and
cyclin B1 in K652 cells 16 h after treatment with the c-Myb siRNA pool or c-Mybex9b siRNA or control siRNA. Cyclin B1 expression was
detected by anti-cyclin B1 antibody (sc-245, Santa Cruz Biotechnology). b-actin levels were measured as loading control. (b) Densitometric
analysis of cyclin B1 levels after siRNA transfection. Densitometric values for cyclin B1 were normalized by the corresponding values for b-actin
and expressed as percentage change, compared with those in control siRNA-transfected cells (taken as 100%). Results are representative of
two different experiments. (c) % of G2/M-phase K562 cells 48 h after siRNA transfection (values represent the mean±s.d. of three independent
experiments; *denotes statistical significance of the differences between scramble- and c-Myb siRNA-transfected cells). (d) % of phospho-
H3-positivity (representative of three independent experiments) in K562 cells 48 h after siRNA transfection.
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We also analyzed the fraction of G2/M-phase cells in c-Myb- or
p89c-Mybex9-silenced K562 cells by evaluating DNA content of
propidium iodide-stained cells and percentage of cells positive for
phospho-histone-H3, which is a marker of M phase. As expected,
the decrease in the cyclin B1 levels was accompanied by a
reduction in the number of cells in G2/M phase (Figure 5c).
Although not statistically significant, in three different experi-
ments, the number of M-phase cells was lower in c-Myb- or
p89c-Mybex9b-siRNA-2 than in control siRNA-transfected K562 cells
(Figure 5d).
p89c-Mybex9b expression affects the response of K562 cells to
treatment with IM
Because expression of p89c-Mybex9b appears to be important for
proliferation and colony formation of K562 cells, we speculated
that it may also influence the response to treatment with IM.
Parental, p89c-Mybex9b- or D(358–452)c-Myb-expressing K562
cells were treated with IM, and cell counts and DNA content
analyses were performed every 24 h.
As expected, expression of D(358–452)c-Myb reduced the IM
sensitivity of K562 cells (Figure 6a); expression of p89c-Mybex9b had
a similar, although less potent, effect as IM-treated p89c-Mybex9b-
expressing K562 cells exhibited a less pronounced decrease in cell
number than parental cells (Figure 6a). Similar effects were
observed upon assessing apoptosis of IM-treated K562 cells; as
expected, IM-treated parental K562 cells showed a high percen-
tage of apoptosis, which increased from 24 to 72 h. In contrast,
apoptosis of IM-treated K562 cells expressing p89c-Mybex9b or
D(358–452)c-Myb was approximately 50% lower than that
of parental cells (Figure 6b). In normal growth conditions,
overexpression of p89c-Mybex9b or D(358–452)c-Myb has no effect
on the proliferation and basal apoptosis of K562 cells
(Supplementary Figure 2).
We also assessed the effect of c-Myb downregulation on
IM-treated K562 cells. Parental cells transfected with the c-Myb
siRNA pool, p89c-Mybex9b isoform-specific or control siRNAs were
counted and analyzed by flow cytometry 24, 48 and 72 h after IM
treatment. Downregulation of c-Myb or p89c-Mybex9b enhanced the
proliferation inhibitory effects of IM, compared with cells
transfected with the control siRNA (at 72 h, B60% fewer cells
than in control siRNA-transfected K562 cells) (Figure 6c). Evalua-
tion of apoptosis by DNA content analysis showed a similar
pattern: c-Myb-silenced cells exhibited increased apoptosis
compared with cells transfected with control siRNAs. Apoptotic
cells were slightly more numerous after transfection with c-Myb
siRNAs than with the p89c-Mybex9b-specific siRNA but the
differences were not significant (Figure 6d).
We also assessed the relationship between levels of p89c-Mybex9b
and colony formation after IM treatment. Thus, parental or
Figure 6. Effects of p89c-Mybex9b levels on viability of IM-treated K562 cells. (a) Cell count and (b) apoptosis of IM-treated parental, p89c-Mybex9b
or D(358–452)c-Myb ectopically expressing K562 cells. (c) Cell count and (d) apoptosis of IM-treated K562 cells transfected with the c-Myb
siRNA pool or c-Mybex9b-specific siRNA or control siRNA (values indicate the increase in apoptosis at 24, 48 and 72 h over the corresponding
normalized apoptosis at time 0 and represent the mean±s.d. of three independent experiments); colony formation of IM-treated: (e) parental,
p89c-Mybex9b or D(358–452)c-Myb ectopically expressing K562 cells and (f ) K562 cells transfected with c-Myb siRNA pool or c-Mybex9b-specific
siRNA or control siRNA. Values are expressed as % of colonies from treated cells compared with those derived from the corresponding
untreated cells taken as 100%. *denotes statistical significance of the differences between control (parental or scramble-transfected) and
experimental (c-Myb ectopically expressed or siRNA-transfected) groups.
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ectopically expressing p89c-Mybex9b or D(358–452)c-Myb K562 cells
were treated for 24 h with IM (1 mM) and plated in methylcellulose
(500 cells per plate, in the presence of 1 mM IM); colonies were
counted after 6 days.
Consistent with the effects on cell proliferation, expression of
the p89c-Mybex9b isoform enhanced the number of clonogenic cells
after IM treatment (13.8% and 6.5% of residual clonogenic cells
in p89c-Mybex9b-expressing versus parental K562 cells). Residual
colonies formed by p89c-Mybex9b or D(358–452)c-Myb-expressing
K562 cells were nearly identical (Figure 6e).
Colony assays were also performed after c-Myb or p89c-Mybex9b-
specific siRNA tranfection and IM treatment of K562 cells. As
expected, the combination of Myb downregulation and IM
treatment caused a marked decrease in the clonogenic potential
of K562 cells. Residual colony formation of cells transfected with
the c-Myb siRNA pool or p89c-Mybex9b-siRNA was similar (1.1%
and 1.9%, respectively) and lower of that from cells transfected
with control siRNAs (3.1%) (Figure 6f). Together, these data
suggest that expression of the p89c-Mybex9b isoform can modulate
the effects of IM in K562 cells.
Inhibition of p89c-Mybex9b suppresses colony formation of normal
and CML CD34þ progenitors
The role of p89c-Mybex9b expression was also assessed in
colony-formation assays of CD34þ cells from healthy donors
and CML patients.
Normal human CD34þ cells (n¼ 3) were transfected with the
c-Myb siRNA pool or a p89c-Mybex9b-specific siRNA or the control
siRNA. 24 h after transfection, levels of c-Myb proteins were tested
and cells were plated for colony-formation assays. A representa-
tive western blot shows that levels of p75c-Myb and p89c-Mybex9b
were completely downregulated in cells transfected with the
c-Myb siRNA pool, whereas transfection with p89 c-Mybex9b-siRNA
reduced only the levels of the p89c-Mybex9b isoform (Figure 7a).
Normal CD34þ cells transfected with the c-Myb siRNA pool or the
p89c-Mybex9b-specific siRNA formed fewer colonies than control
siRNA-transfected cells (B33% and 28% inhibition, respectively;
range: 23–43% and 22–37%, respectively) (Figure 7b).
Peripheral blood CD34þ cells from CML chronic-phase patients
(n¼ 5) were also transfected with c-Myb or control siRNAs. Like in
normal CD34þ cells, expression of p75c-Myb and p89c-Mybex9b was
markedly downregulated in CML CD34þ cells transfected with
the c-Myb siRNA pool, whereas only p89c-Mybex9b levels decreased
in cells transfected with p89c-Mybex9b-siRNA (Figure 7c).
Transfected CML CD34þ cells were seeded in cytokine-supple-
mented methylcellulose and colonies were counted 9 days later.
Colonies arising from cells transfected with the c-Myb siRNA pool
or p89c-Mybex9b-siRNA were fewer (63% and 41% decrease,
respectively; range: 50–90% and 28–58% , respectively) than
those from the scramble siRNA-transfected counterpart
(Figure 7d).
Together, these results suggest that expression of p89c-Mybex9b
is more important for colony formation of CML than normal
CD34þ progenitors.
DISCUSSION
The c-Myb gene generates multiple transcripts that encode the
predominant p75c-Myb isoform and, potentially, several less-
abundant species.46 However, only the p89c-Mybex9b isoform is
readily detectable in hematopoietic cells, suggesting that other
alternatively spliced transcripts are too rare to generate detectable
proteins or that the encoded gene products are unstable and
rapidly degraded. p89c-Mybex9b accounts for 10–15% of total c-Myb
protein, an amount that could be biologically relevant because
Figure 7. Colony formation of c-Myb or p89c-Mybex9b siRNA-transfected normal or CML CD34þ progenitors. (a and c) Western blots show levels
of p75c-Myb and p89c-Mybex9b in a representative sample of normal (a) or CML (c) CD34þ cells after transfection with control or c-Myb siRNAs;
b-actin was detected as loading control. (b and d) Methylcellulose colony formation of normal (n¼ 3) (b) or CML (n¼ 5) (d) CD34þ cells
transfected with control or c-Myb siRNAs. Values of colony formation are mean±s.d.; all the experiments were performed in triplicate.
*denotes statistical significance of the differences in colony formation between cells transfected with control siRNA, the c-Myb siRNA pool, or
the c-Mybex9b-specific siRNA.
p89c-Mybex9b in BCR/ABL leukemogenesis
G Manzotti et al
9
& 2012 Macmillan Publishers Limited Blood Cancer Journal
small changes in the levels of c-Myb can affect lineage choice
and progenitor cell frequencies in normal hematopoiesis.47,48
p89c-Mybex9b isoform-specific knockout mice have no apparent
defect in the number of steady-state mature hematopoietic
cells,40 but the long-term proliferative potential, survival and
differentiation of specific progenitor subsets was not investigated
in detail. Although this study suggests that, in normal cells, loss of
p89c-Mybex9b expression is compensated by expression of the more
abundant p75c-Myb isoform, it is conceivable that expression of
p89c-Mybex9b is biologically more relevant in leukemic cells, which
typically rely on c-Myb expression more than their normal
counterparts.18,21
We show here that perturbation of p89c-Mybex9b levels by
ectopic expression or by specific downregulation modulates the
proliferation, survival and IM sensitivity of BCR/ABL-transformed
cells. The increased proliferation, survival and IM resistance
of p89c-Mybex9b ectopically expressing K562 cells is reminiscent
of similar effects observed in experiments carried out with artificial
degradation-resistant mutants of the c-Myb LZ-NRD.17
The similarity of the effects is likely to reflect the comparable
increase in protein stability and transactivation ability of
the artificial c-Myb mutants and the p89c-Mybex9b isoform.
Of greater interest, downregulation of the p89c-Mybex9b isoform
was associated with reduced proliferation and colony formation
and with enhanced IM sensitivity of BCR/ABL-transformed cells
comparable to that observed after transfection with the c-Myb
siRNA pool, which caused the downregulation of both
the predominant p75c-Myb isoform and the less-abundant
p89c-Mybex9b species.
An explanation for these surprising findings could be that
downregulation of p89c-Mybex9b expression suppresses an
autoregulatory loop, which may maintain elevated levels of the
p75c-Myb isoform.49 However, this putative mechanism does not
appear to be involved because p75c-Myb levels were not reduced
in p89c-Mybex9b-silenced cells.
Another possibility is that disruption of the LZ-NRD in the
p89c-Mybex9b isoform prevents protein–protein interactions with
p75c-Myb or p75c-Myb-interacting proteins, allowing p89c-Mybex9b to
escape the negative regulation imposed by p75c-Myb and/or its
interacting proteins.50,51 Consistent with this interpretation,
co-immunoprecipitation assays showed that p75c-Myb interacted
with p89c-Mybex9b less efficiently than it did with itself
(Supplementary Figure 3).
Thus, the biological effects of c-Myb in p210BCR/ABL-
transformed cells might be exerted, to a large extent, by the
less-abundant but more potent p89c-Mybex9b isoform.
The fact that p89c-Mybex9b is a more potent transactivator of
p75c-Myb and downregulation of p89c-Mybex9b is almost as effective
as the combined downregulation of p75c-Myb and p89c-Mybex9b
in inducing a decrease in the expression of the c-Myb-target cyclin
B1 supports this interpretation, although the entire catalogue
of c-Myb-target genes should be examined.
Lastly, the preferential requirement of the p89c-Mybex9b isoform
by BCR/ABL-transformed cells may depend on the regulation of a
specific gene subset, which may be distinct from that regulated by
p75c-Myb.39 This possibility is supported by the observation that
restoring the expression of either the p75c-Myb or p89c-Mybex9b
isoform rescued only in part the inhibition of colony formation
induced by downregulation of both, consistent with non-
overlapping effects of the two isoforms.
Regardless of the mechanisms involved, the observation that
the effects of c-Myb in leukemic cells are, in a significant part, due
to minute amounts of an alternatively spliced isoform raises new
questions regarding the elusive oncogenic potential of c-Myb.
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